Methyltransferases


Also found in: Medical.

Methyltransferases

 

(also transmethylases), enzymes of the class of transferases; they catalyze transmethylation of methyl groups.

Mentioned in ?
References in periodicals archive ?
Mode of transposition and expression of 16S rRNA methyltransferases gene rmtC accompanied by ISEcp1.
Raymond Trievel, Associate Professor of Biological Chemistry at the University of Michigan added, "The development of the SAM-Screener[TM] provides new chemical tools for studying substrate recognition by methyltransferases and offers a flexible platform for identifying SAM-competitive inhibitors, particularly for methyltransferases that are targets for the design of novel therapeutics to treat cancer and other diseases.
Our previous work has shown the DNA methyltransferases (DNMT1, DNMT3a, DNMT3b) are differentially expressed in the Ames dwarf and GHtg murine liver compared to their wild-type counterparts suggesting that GH status may be involved.
18) Alteration in DNA methyltransferases plays an important role in the development of cancer.
Holden and colleagues studied a bacterial methyltransferase involved in the production of tetronitrose, a component of the promising anti-cancer agent, tetrocarcin, and the antibiotic kijanimicin.
They form permanent chemical bonds with the enzyme, thereby catching the methyltransferases one by one, so that no more genes are being silenced.
These include histone methyltransferases, demethylases and ubiquitin-related enzymes.
Methylation is an important epigenetic feature of DNA, which is catalyzed by DNA methyltransferases with AdoMet as a methyl donor.
Epigenetic modulation through methylation as directed by DNA methyltransferases is particularly relevant in understanding tumorogenic etiology.
The company has other research and development programs to develop small molecule inhibitors of DNA methyltransferases, histone deacetylases, beta-lactamases and other enzyme targets.
Epizyme and Celgene International Sarl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced the formation of a strategic partnership to discover, develop and commercialize personalized therapeutics for patients with genetically-defined cancers by inhibiting histone methyltransferases (HMTs), an important epigenetic target class.
Plants experience more extreme environment than mammals, and the evolution of plant methyltransferases may have favoured improved stress adaptation, while in mammals, it may lead to more stable establishment and resetting phases during development.